Radiology, Vol 189, 541-547, Copyright © 1993 by Radiological Society of North America

ARTICLES

Transcatheter chemoembolization of progressive carcinoid liver metastasis

E Therasse, F Breittmayer, A Roche, T De Baere, S Indushekar, M Ducreux, P Lasser, D Elias and P Rougier
Department of Interventional Radiology, Institut Gustave Roussy, Villejuif, France.

PURPOSE: The authors report their experience treating progressive liver metastases from carcinoid tumor with doxorubicin, iodized oil, and gelatin sponge embolization. MATERIALS AND METHODS: Of 23 patients, 18 had carcinoid syndrome and 19 had elevated urinary 5- hydroxyindoleacetic acid (5-HIAA) levels. Relief of symptoms, changes in 5-HIAA levels, and changes in tumor size could be evaluated in 10, 11, and 17 patients, respectively. RESULTS: Symptomatic response was complete (average duration, 29 months) in 70% and partial in 30% of evaluated patients. Biologic response was complete (average duration, 21 months) in 73%, partial in 18%, and minor in 9% of evaluated patients. Morphologic response was complete in 11%, partial in 24%, and minor in 24% of evaluated patients. Survival after diagnosis of primary tumor, diagnosis of hepatic metastases, and first chemoembolization was 81, 47, and 24 months, respectively. Eight patients were alive at the end of the study. No mortality was related to chemoembolization. CONCLUSION: Chemoembolization is safe and effective for palliation of carcinoid liver metastases.

This article has been cited by other articles:

				M. J. Steward, V. S. Warbey, A. Malhotra, M. E. Caplin, J. R. Buscombe, and D. Yu Neuroendocrine Tumors: Role of Interventional Radiology in Therapy RadioGraphics, July 1, 2008; 28(4): 1131 - 1145. [Abstract] [Full Text] [PDF]

				A. S. Ho, J. Picus, M. D. Darcy, B. Tan, J. E. Gould, T. K. Pilgram, and D. B. Brown Long-Term Outcome After Chemoembolization and Embolization of Hepatic Metastatic Lesions from Neuroendocrine Tumors Am. J. Roentgenol., May 1, 2007; 188(5): 1201 - 1207. [Abstract] [Full Text] [PDF]

				J. Fromigue, T. De Baere, E. Baudin, C. Dromain, S. Leboulleux, and M. Schlumberger Chemoembolization for Liver Metastases from Medullary Thyroid Carcinoma J. Clin. Endocrinol. Metab., July 1, 2006; 91(7): 2496 - 2499. [Abstract] [Full Text] [PDF]

				M. K. G. McStay, D. Maudgil, M. Williams, J. M. Tibballs, A. F. Watkinson, M. E. Caplin, and J. R. Buscombe Large-Volume Liver Metastases from Neuroendocrine Tumors: Hepatic Intraarterial 90Y-DOTA-Lanreotide as Effective Palliative Therapy Radiology, November 1, 2005; 237(2): 718 - 726. [Abstract] [Full Text] [PDF]

				G. A. Kaltsas, G. M. Besser, and A. B. Grossman The Diagnosis and Medical Management of Advanced Neuroendocrine Tumors Endocr. Rev., June 1, 2004; 25(3): 458 - 511. [Abstract] [Full Text] [PDF]

				K. Stuart Chemoembolization in the Management of Liver Tumors Oncologist, October 1, 2003; 8(5): 425 - 437. [Abstract] [Full Text] [PDF]

				C. Loewe, M. Schindl, M. Cejna, B. Niederle, J. Lammer, and S. Thurnher Permanent Transarterial Embolization of Neuroendocrine Metastases of the Liver Using Cyanoacrylate and Lipiodol: Assessment of Mid- and Long-Term Results Am. J. Roentgenol., May 1, 2003; 180(5): 1379 - 1384. [Abstract] [Full Text] [PDF]

				R. G. Abramson, M. P. Rosen, L. J. Perry, D. P. Brophy, S. L. Raeburn, and K. E. Stuart Cost-effectiveness of Hepatic Arterial Chemoembolization for Colorectal Liver Metastases Refractory to Systemic Chemotherapy Radiology, August 1, 2000; 216(2): 485 - 491. [Abstract] [Full Text]

				J. Gates, G. G. Hartnell, K. E. Stuart, and M. E. Clouse Chemoembolization of Hepatic Neoplasms: Safety, Complications, and When to Worry RadioGraphics, March 1, 1999; 19(2): 399 - 414. [Abstract] [Full Text] [PDF]

				J.-S. Yu, K. W. Kim, M.-S. Park, and S.-W. Yoon Bile Duct Injuries Leading to Portal Vein Obliteration after Transcatheter Arterial Chemoembolization in the Liver: CT Findings and Initial Observations Radiology, November 1, 2001; 221(2): 429 - 436. [Abstract] [Full Text] [PDF]